<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-886
Date of Submission: 2024-09-02

This report was submitted by a Pharmacist from Goodwin, Garner and Brewer Medical Center concerning patient ANON-PX-6337. The subject is a 33-year-old other with a significant medical history including anxiety, migraines, coronary artery disease, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Intramuscular route at a dosage of 147mg, initiated on 2024-07-06 for Major depressive disorder and discontinued on 2024-08-27.

On approximately 2024-07-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Headache, Pruritus. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Guy myself family why card. Year place future any much majority.</data>
report_id: ADR-2024-886
report_date: '2024-09-02'
patient_details:
  patient_id: ANON-PX-6337
  gender: Other
  relevant_history:
  - anxiety
  - migraines
  - coronary artery disease
  - hypertension
  age_at_reaction: 33
suspected_drugs:
- drug_name: Sertraline
  dosage: 147mg
  route_of_administration: Intramuscular
  start_date: '2024-07-06'
  indication_for_use: Major depressive disorder
  drug_class: SSRI
  end_date: '2024-08-27'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2024-07-23'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Headache
  onset_date: '2024-07-23'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
- symptom_name: Pruritus
  onset_date: '2024-07-23'
  severity: Life-threatening
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 2
reporting_facility: Goodwin, Garner and Brewer Medical Center
reporter_type: Pharmacist
notes: Guy myself family why card. Year place future any much majority.
